EGFR and neoplasm: TKIs act to inhibit EGFR kinase activity, thus attenuating downstream signal transduction (22); whereas anti-EGFR antibodies serve to block ligand binding to the extracellular portion of EGFR leading to inhibition of downstream signaling, but also have the capacity to leverage cytotoxic immune cells to induce anti-tumor antibody-dependent cellular cytotoxicity (ADCC) (23, 24).